Announcement on Proposed Winning Bids for the 12th Batch of National Centralized Drug Procurement
The company and its board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false representations, misleading statements, or material omissions.
Recently, Zhejiang AngliKang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") and its subsidiary Fujian Haixi United Pharmaceutical Co., Ltd. (hereinafter referred to as "Haixi Pharmaceutical") participated in the bidding for the 12th batch of national centralized drug procurement organized by the National Joint Procurement Office for Drugs. According to the "12th Batch of National Centralized Drug Procurement Proposed Winning Bid Results" (GY-YD2026-1) released by the National Joint Procurement Office for Drugs on July 31, 2026, the Company's Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, Sacubitril Valsartan Sodium Tablets, and Haixi Pharmaceutical's Sevoflurane for Inhalation were proposed to be selected in the 12th batch of centralized drug procurement. The relevant proposed winning bid information is hereby announced as follows: